Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3217–3240 of 185,116 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NOT program Clear all

Conditions: Fabry Disease
Interventions: migalastat HCl, ERT; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 5 more

Conditions: Carcinoma
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Not listed
Enrollment: 1,243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 5
States / cities: Orlando, Florida • St Louis, Missouri • New Brunswick, New Jersey + 1 more

Conditions: Endometriosis
Interventions: elagolix, estradiol/norethindrone acetate (E2/NETA); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 37
States / cities: Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more

Conditions: Metabolic Syndrome
Interventions: Etanercept, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obstructive Sleep Apnea of Child
Interventions: Cytokine from blood; Diagnostic Test
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 5 Years to 10 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Covid19, Androgen Receptor Gene Overexpression
Interventions: COVID-19 Androgen Sensitivity Test (CoVAST); Genetic
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 90 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Irvine, California

Conditions: Contact Lens Care
Interventions: AOSEPT Plus and AOCup lens case, AOSEPT Plus with HydraGlyde and AOCup lens case, Habitual contact lenses; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 7 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Healthy Adults
Interventions: Prifetrastat; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hearing Loss
Interventions: Not listed
Lead sponsor: Med-El Corporation; Industry
Eligibility: Up to 24 Months
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 5
States / cities: Augusta, Georgia • Durham, North Carolina • Nashville, Tennessee + 2 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chlorhexidine Gluconate Cloths, Infection; Cesarean Section, Infectious Morbidity, Surgical Site Infections, Endometritis
Interventions: 2% chlorhexidine gluconate (CHG) cloth, Placebo cloth; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,356 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Head and Neck Cancer
Interventions: GI-6207 [Recombinant Saccharomyces Cerevisia, (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)]); Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Diffuse Optical Tomography (DOT) System; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
Interventions: eHealth Mindfulness-based Music Therapy (eMBMT), eHealth Mindfulness Meditation (eMM); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Solid Tumor
Interventions: LY3022855, Durvalumab, Tremelimumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 7
States / cities: Denver, Colorado • Sarasota, Florida • Atlanta, Georgia + 2 more

Conditions: Ventricular Tachycardia
Interventions: Endocardial ablation, Endocardial- Epicardial ablation, Antiarrhythmic medications; Procedure · Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lung Disease, Pulmonary Lobectomy
Interventions: Standard Tissue Closure Techniques, PleuraSeal Lung Sealant System; Procedure · Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Scar, Laser Therapy
Interventions: Laser treatment with Purpuric settings, Laser treatment with Nonpurpuric settings, No treatment; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Chronic Pancreatitis, Pancreatic Cancer
Interventions: triamcinolone, 98% dehydrated alcohol; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Body Weight
Interventions: Device: FitBit Flex wrist band, Device: FitBit Aria weight scale, Diet Intake Messages, Behavioral Counseling; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atherosclerosis, Coronary Artery Disease
Interventions: OMEGA™ Monorail Coronary Stent System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 22
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Loma Linda, California + 18 more

Conditions: Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment; Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 7
States / cities: Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more

Conditions: Hypertension
Interventions: barbershop-based BP measurement; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chikungunya Virus Infection
Interventions: Biological Vaccine VLA1553; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Coral Gables, Florida • Fort Myers, Florida • Ponte Vedra, Florida + 9 more

Search by objective public record fields.

A Study of Patients With Fabry Disease (US Specific)

Registry for Proton Beam Radiation Therapy

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

Study of TNF-Antagonism in the Metabolic Syndrome (II)

Cytokine Persistence as a Marker of Inflammation in the at Risk, Low Socioeconomic Status Pediatric Population

COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression

AOSEPT (CLEAR CARE) PLUS Study

A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults

Littlears Auditory Questionnaire: Validation Study in CI Children

Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis

STRIPES Study: Study To Reduce Infection Post cEsarean Section

An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

Optical Tomography in Prostate Cancer

eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Comparison of Ventricular Tachycardia Ablation Strategies in Patients With Ischemic Cardiomyopathy

PleuraSeal Post Market Study (Europe)

Treatment of Surgical Scars Using the Pulsed Dye Laser

A Prospective Study of EUS Guided Celiac Block

Weight Management Among Breast Cancer Survivors

The OMEGA Clinical Trial

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

Cut Your Pressure Too: The Altadena Barbershop Blood Pressure Study, Phase 2 (Intervention Pilot Study)

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults